Literature DB >> 7831794

In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1.

M Yu1, E Poeschla, O Yamada, P Degrandis, M C Leavitt, M Heusch, J K Yees, F Wong-Staal, A Hampel.   

Abstract

We have constructed a hairpin ribozyme targeted to cleave a conserved sequence in the HIV-1 pol gene. The ribozyme was modified to include a structure-stabilizing tetraloop. In vitro studies revealed a cleavage efficiency unprecedented for hairpin ribozymes (Kcat/Km = 75 min-1 microM-1). Stable retroviral vector transduction of this ribozyme gene in T-cell lines resulted in long-term ribozyme expression. As compared to control vector transduced T-cells, the pol ribozyme-transduced cells exhibited significant inhibition of different strains of HIV-1 virus production; this protection was greater when ribozyme expression was driven from an internal pol III promoter (adenovirus VA1) than when driven by a pol II promoter (the MMLV LTR). These results further demonstrate the potential of hairpin ribozymes as anti-HIV gene therapy agents and suggest possibilities for employing combinations of independently targeted hairpin ribozymes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7831794     DOI: 10.1016/s0042-6822(95)80053-0

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

Review 1.  The hairpin ribozyme. Discovery, mechanism, and development for gene therapy.

Authors:  R Shippy; R Lockner; M Farnsworth; A Hampel
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

2.  Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes.

Authors:  L M Alvarez-Salas; A E Cullinan; A Siwkowski; A Hampel; J A DiPaolo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

Review 3.  Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.

Authors:  M Clementi; S Menzo; P Bagnarelli; A Valenza; S Paolucci; R Sampaolesi; A Manzin; P E Varaldo
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 4.  Development of HIV vectors for anti-HIV gene therapy.

Authors:  E Poeschla; P Corbeau; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1.

Authors:  O Yamada; G Kraus; L Luznik; M Yu; F Wong-Staal
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

6.  Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint.

Authors:  C M Flory; P A Pavco; T C Jarvis; M E Lesch; F E Wincott; L Beigelman; S W Hunt; D J Schrier
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

Review 7.  Anti-HIV ribozymes.

Authors:  L Q Sun; J A Ely; W Gerlach; G Symonds
Journal:  Mol Biotechnol       Date:  1997-06       Impact factor: 2.860

8.  A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection.

Authors:  M A Biasolo; A Radaelli; L Del Pup; E Franchin; C De Giuli-Morghen; G Palu
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 9.  RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside.

Authors:  Skye J Zeller; Priti Kumar
Journal:  Yale J Biol Med       Date:  2011-09

Review 10.  Antisense inhibition of virus infections.

Authors:  R E Kilkuskie; A K Field
Journal:  Adv Pharmacol       Date:  1997
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.